APA

Hannan E. J., O'Leary D. P., MacNally S. P., Kay E. W., Farrell M. A., Morris P. G., Power C. P. & Hill A. D. K. (20180115). The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy. : Medicine.

Chicago

Hannan Enda J, O'Leary Donal P, MacNally Stephen P, Kay Elaine W, Farrell Michael A, Morris Patrick G, Power Colm P and Hill Arnold D K. 20180115. The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy. : Medicine.

Harvard

Hannan E. J., O'Leary D. P., MacNally S. P., Kay E. W., Farrell M. A., Morris P. G., Power C. P. and Hill A. D. K. (20180115). The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy. : Medicine.

MLA

Hannan Enda J, O'Leary Donal P, MacNally Stephen P, Kay Elaine W, Farrell Michael A, Morris Patrick G, Power Colm P and Hill Arnold D K. The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy. : Medicine. 20180115.